Johnson & Johnson's (JNJ.US) antibody therapy met the primary endpoint in its Phase 3 trial, significantly delaying the progression of high-risk SMM
AInvestWednesday, Nov 6, 2024 2:30 am ET
1min read
JNJ --
MET --
SMMU --

The American Society of Hematology (ASH) has released abstracts for some of the research that will be presented at its 2024 meeting. Among them, Darzalex (daratumumab), an anti-CD38 antibody developed by Johnson & Johnson (JNJ.US), met the primary endpoint in the phase 3 Aquila trial, significantly delaying disease progression in high-risk smoldering multiple myeloma (SMM) patients.The abstract states that Darzalex monotherapy was well tolerated and showed statistically significant and clinically meaningful benefits in preventing or delaying progression to active multiple myeloma (MM) compared to active monitoring in high-risk SMM patients.Public information shows that SMM is the pre-symptomatic stage of MM, which may develop into active MM, and currently there is no approved treatment. However, recent studies have shown that patients with high risk of progressing to MM may benefit from early treatment. Darzalex is a humanized monoclonal antibody targeting CD38, which has been approved for the treatment of relapsed/refractory MM and is used in combination with standard therapy for the first-line treatment of newly diagnosed MM. The Aquila study aims to determine whether Darzalex is more effective than active monitoring in delaying the progression of MM.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.